Dako A/S and Amgen (AMGN) to Collaborate in Development of a Companion Diagnostic for an Amgen Investigational Cancer Therapy  
1/10/2012 8:23:11 AM

Dako, a world leading independent cancer diagnostic supplier with 45 years of experience in pathology, announced today that it has entered into a development and collaboration agreement with Amgen Inc. (Nasdaq: AMGN) to develop a diagnostic test for an Amgen cancer drug candidate targeted for a rare and deadly cancer. "I am proud to announce that Dako and Amgen have succeeded in putting together a business model that supports the concurrent development of drug and diagnostics for a low incidence cancer - something that has been difficult to achieve in the industry until now," says Lars Holmkvist, Dako's chief executive officer.